MX2022010922A - Compuestos para su uso en el tratamiento de la infeccion por coronavirus. - Google Patents

Compuestos para su uso en el tratamiento de la infeccion por coronavirus.

Info

Publication number
MX2022010922A
MX2022010922A MX2022010922A MX2022010922A MX2022010922A MX 2022010922 A MX2022010922 A MX 2022010922A MX 2022010922 A MX2022010922 A MX 2022010922A MX 2022010922 A MX2022010922 A MX 2022010922A MX 2022010922 A MX2022010922 A MX 2022010922A
Authority
MX
Mexico
Prior art keywords
treatment
compounds
coronavirus infection
sub
coronavirus
Prior art date
Application number
MX2022010922A
Other languages
English (en)
Inventor
Marín Pablo Avilés
González Alejandro Losada
Muñoz Salvador Fudio
Sousa-Faro José Maria Fernández
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2022010922A publication Critical patent/MX2022010922A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un compuesto de fórmula general I (ver Fórmula) en donde X, Y, n, p, q y R1-R17 tienen diversos significados, para su uso en el tratamiento de la infección por coronavirus.
MX2022010922A 2020-03-02 2021-03-02 Compuestos para su uso en el tratamiento de la infeccion por coronavirus. MX2022010922A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382816 2020-09-16
EP20382815 2020-09-16
PCT/EP2021/055137 WO2021175826A1 (en) 2020-03-02 2021-03-02 Compounds for use in the treatment of coronavirus infection

Publications (1)

Publication Number Publication Date
MX2022010922A true MX2022010922A (es) 2022-09-29

Family

ID=74797953

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010922A MX2022010922A (es) 2020-03-02 2021-03-02 Compuestos para su uso en el tratamiento de la infeccion por coronavirus.

Country Status (16)

Country Link
US (1) US20230158102A1 (es)
EP (1) EP4114436A1 (es)
JP (1) JP2023517295A (es)
KR (1) KR20220151181A (es)
CN (1) CN115666615A (es)
AU (1) AU2021232534A1 (es)
BR (1) BR112022017008A2 (es)
CA (1) CA3169791A1 (es)
CL (1) CL2022002398A1 (es)
CO (1) CO2022014115A2 (es)
IL (1) IL296066A (es)
MX (1) MX2022010922A (es)
PE (1) PE20231069A1 (es)
TW (1) TW202144380A (es)
UY (1) UY39108A (es)
WO (1) WO2021175826A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
CN1819837A (zh) 2003-03-21 2006-08-16 玛德琳·M.·茹利 Tamandarin类似物及其片段以及制备和使用方法
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds

Also Published As

Publication number Publication date
KR20220151181A (ko) 2022-11-14
PE20231069A1 (es) 2023-07-17
US20230158102A1 (en) 2023-05-25
UY39108A (es) 2021-09-30
JP2023517295A (ja) 2023-04-25
CA3169791A1 (en) 2021-09-10
EP4114436A1 (en) 2023-01-11
CL2022002398A1 (es) 2023-06-30
CO2022014115A2 (es) 2022-11-18
AU2021232534A1 (en) 2022-10-06
CN115666615A (zh) 2023-01-31
BR112022017008A2 (pt) 2022-10-11
IL296066A (en) 2022-11-01
TW202144380A (zh) 2021-12-01
WO2021175826A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
EG25017A (en) N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials.
EA200601896A1 (ru) Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
IN2012DN00999A (es)
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
DE60214591D1 (en) Pyrazolpyrimidinfungizide
TW200512208A (en) Piperazine derivatives
NO20052788L (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
NO20065075L (no) Ikke-nukleosidbaserte revers-transkriptase-inhibitorer.
SE9904108D0 (sv) Nya föreningar
HK1085675A1 (en) Anticancer compounds
BRPI0409230A (pt) formas de dosagem compreendendo ag013736
TW200716571A (en) Heterocyclic reverse transcriptase inhibitors
MX2021011286A (es) Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia.
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
MXPA04006041A (es) Antivirales de piridoquinoxalina.
AP2002002466A0 (en) 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS.
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
TW200600084A (en) Anti-coronavirus compounds
MX2022010922A (es) Compuestos para su uso en el tratamiento de la infeccion por coronavirus.
NO20062307L (no) Spirofuropyridinarylderivater
MX2023009677A (es) Inhibidores de enzimas.
MXPA05013034A (es) N-alquinil-2-heteroariloxialquilamidas para uso como fungicidas.
SE0102058D0 (sv) New Salts II
DE602004030536D1 (de) Pyrrolidinohydrochinazoline